Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice

Immunology Letters

Volumn 106, Issue 2, 2006, Pages 154-162

  Hur, Wonhee ^a   Cho, Mi La ^a   Yoon, Seung Kew ^a   Kim, So Yeon ^a   Ju, Ji Hyeon ^a   Jhun, Joo Yeon ^a   Heo, Seong Bum ^a   Moon, Young Mee ^a   Min, So Youn ^a   Park, Sung Hwan ^a   Kim, Ho Youn ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Arthritis; Gene therapy; IL 1 receptor antagonist; IL 1 receptor antagonist deficient mice

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN TYPE 2; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PROTEOGLYCAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE; ANTIBODY BLOOD LEVEL; ARTICLE; ARTICULAR CARTILAGE; AUTOIMMUNE DISEASE; CHRONIC ARTHRITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; GENE INSERTION; GENE TARGETING; GENE TRANSFER; HISTOPATHOLOGY; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATORY INFILTRATE; JOINT BIOPSY; JOINT SWELLING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SPECIES COMPARISON; TH1 CELL; TH2 CELL; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; GENE THERAPY; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; JOINTS; MICE; MICE, KNOCKOUT; SIALOGLYCOPROTEINS; TH2 CELLS;

EID: 33747094421     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2006.05.006     Document Type: Article

References (46)

1. Taylor P.C. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 3 3 (2003) 323-328
2. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA, Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proceedings Of The National Academy Of Sciences Of The United States Of America 1984; 81(24):7907-7911.
3. Dinarello C.A., Cannon J.G., Mier J.W., Bernheim H.A., LoPreste G., Lynn D.L., et al. Reuben et a: Multiple biological activities of human recombinant interleukin 1. J Clin Invest 77 6 (1986) 1734-1739
4. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
5. Arner E.C., and Pratta M.A. Independent effects of interleukin-1 on proteoglycan breakdown, proteoglycan synthesis, and prostaglandin E2 release from cartilage in organ culture. Arthritis Rheum 32 3 (1989) 288-297
6. Bhatnagar R., Penfornis H., Mauviel A., Loyau G., Saklatvala J., and Pujol J.P. Interleukin-1 inhibits the synthesis of collagen by fibroblasts. Biochem Int 13 4 (1986) 709-720
7. Borghaei R.C., Rawlings Jr. P.L., and Mochan E. Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts. Arthritis Rheum 41 8 (1998) 1398-1406
8. Martel-Pelletier J., Zafarullah M., Kodama S., and Pelletier J.P. In vitro effects of interleukin 1 on the synthesis of metalloproteases, TIMP, plasminogen activators and inhibitors in human articular cartilage. J Rheumatol Suppl 27 (1991) 80-84
9. Meller D., Li D.Q., and Tseng S.C. Regulation of collagenase, stromelysin, and gelatinase B in human conjunctival and conjunctivochalasis fibroblasts by interleukin-1beta and tumor necrosis factor-alpha. Invest Ophthalmol Vis Sci 41 10 (2000) 2922-2929
10. Rayan V., and Hardingham T. The recovery of articular cartilage in explant culture from interleukin-1 alpha: effects on proteoglycan synthesis and degradation. Matrix Biol 14 3 (1994) 263-271
11. Goldring S.R. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 42 Suppl. 2 (2003) ii11-ii16
12. Dinarello C.A. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 4 4 (2004) 378-385
13. Arend W.P., and Dayer J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 38 2 (1995) 151-160
14. Eisenberg S.P., Evans R.J., Arend W.P., Verderber E., Brewer M.T., Hannum C.H., et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343 6256 (1990) 341-346
15. Hannum C.H., Wilcox C.J., Arend W.P., Joslin F.G., Dripps D.J., Heimdal P.L., et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343 6256 (1990) 336-340
16. Furst D.E. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 26 12 (2004) 1960-1975
17. Fleischmann R.M., Schechtman J., Bennett R., Handel M.L., Burmester G.-R., Tesser J., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48 4 (2003) 927-934
18. Schiff M.H. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis 59 Suppl. 1 (2000) i103-i108
19. Jeong J.G., Kim J.M., Ho S.H., Hahn W., Yu S.S., and Kim S. Electrotransfer of human IL-1Ra into skeletal muscles reduces the incidence of murine collagen-induced arthritis. J Gene Med 6 10 (2004) 1125-1133
20. Chang D.M., Shyue S.K., Liu S.H., Chen Y.T., Yeh C.Y., Lai J.H., et al. Dual biological functions of an interleukin-1 receptor antagonist-interleukin-10 fusion protein and its suppressive effects on joint inflammation. Immunology 112 4 (2004) 643-650
21. Kim J.M., Jeong J.G., Ho S.H., Hahn W., Park E.J., Kim S., et al. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther 10 18 (2003) 1543-1550
22. Inoue K., Masuko-Hongo K., Okamoto M., and Nishioka K. Efficacy of daily compared to intermittent administration of IL-1Ra for protection against bone and cartilage destruction in collagen-challenged mice. Clin Exp Rheumatol 21 1 (2003) 33-39
23. van de Loo F.A., Smeets R.L., and van den Berg W.B. Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients?. Arthritis Res Ther 6 5 (2004) 183-196
24. Bessis N., Doucet C., Cottard V., Douar A.M., Firat H., Jorgensen C., et al. Gene therapy for rheumatoid arthritis. J Gene Med 4 6 (2002) 581-591
25. Horai R., Asano M., Sudo K., Kanuka H., Suzuki M., Nishihara M., et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1 alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 187 9 (1998) 1463-1475
26. Horai R., Saijo S., Tanioka H., Nakae S., Sudo K., Okahara A., et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191 2 (2000) 313-320
27. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48 10 (2003) 2741-2749
28. Imafuku Y., Yoshida H., and Yamada Y. Reactivity of agalactosyl IgG with rheumatoid factor. Clin Chim Acta 334 1-2 (2003) 217-223
29. Millauer N., Zuercher A.W., Miescher S.M., Gerber H.A., Seitz M., and Stadler B.M. High IgE in rheumatoid arthritis (RA) patients is complexed with anti-IgE autoantibodies. Clin Exp Immunol 115 1 (1999) 183-188
30. Kim S.H., Evans C.H., Kim S., Oligino T., Ghivizzani S.C., and Robbins P.D. Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res 2 4 (2000) 293-302
31. Woods J.M., Katschke K.J., Volin M.V., Ruth J.H., Woodruff D.C., Amin M.A., et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 166 2 (2001) 1214-1222
32. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 8930 (1994) 1105-1110
33. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 22 (2000) 1594-1602
34. Arend W.P., Malyak M., Smith Jr. M.F., Whisenand T.D., Slack J.L., Sims J.E., et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 153 10 (1994) 4766-4774
35. Moreland L.W., Margolies G., Heck Jr. L.W., Saway A., Blosch C., Hanna R., et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 23 11 (1996) 1849-1855
36. Arend W.P. Interleukin-1 receptor antagonist. Adv Immunol 54 (1993) 167-227
37. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41 12 (1998) 2196-2204
38. The IL-1Ra Arthritis Study Group, Campion G.V., Lebsack M.E., Lookabaugh J., Gordon G., and Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39 7 (1996) 1092-1101
39. Evans C.H., Robbins P.D., Ghivizzani S.C., Wasko M.C., Tomaino M.M., Kang R., et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 102 24 (2005) 8698-8703
40. Horai R., Nakajima A., Habiro K., Kotani M., Nakae S., Matsuki T., et al. TNF-alpha is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 114 11 (2004) 1603-1611
41. Bakker A.C., Joosten L.A., Arntz O.J., Helsen M.M., Bendele A.M., van de Loo F.A., et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 40 5 (1997) 893-900
42. Bandara G., Mueller G.M., Galea-Lauri J., Tindal M.H., Georgescu H.I., Suchanek M.K., et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 90 22 (1993) 10764-10768
43. Kim S.H., Lechman E.R., Kim S., Nash J., Oligino T.J., and Robbins P.D. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 6 5 (2002) 591-600
44. Pan R.Y., Chen S.L., Xiao X., Liu D.W., Peng H.J., and Tsao Y.P. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 43 2 (2000) 289-297
45. Roessler B.J., Hartman J.W., Vallance D.K., Latta J.M., Janich S.L., and Davidson B.L. Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector. Hum Gene Ther 6 3 (1995) 307-316
46. Neumann E., Judex M., Kullmann F., Grifka J., Robbins P.D., Pap T., et al. Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway. Gene Ther 9 22 (2002) 1508-1519